ATRC - AtriCure, Inc.
| Previous Close | 27.17 |
| Open | 27.42 |
| Bid | 0.00 x 1300 |
| Ask | 35.74 x 800 |
| Day's Range | 27.02 - 27.43 |
| 52 Week Range | 26.11 - 36.49 |
| Volume | 153,400 |
| Avg. Volume | 197,778 |
| Market Cap | 1.074B |
| Beta (3Y Monthly) | 0.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.56 |
| Earnings Date | Oct 30, 2019 - Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.50 |
- American City Business Journals
The Funded: 6 Bay Area companies raise $274M at midweek
Six Bay Area companies disclosed at midweek that that they raised $274 million in funding and a Redwood City medical device startup was acquired for as much as $300 million. Here are the details on those stories and more.
- Business Wire
AtriCure Completes Acquisition of SentreHEART
AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced that it has completed its previously announced acquisition of SentreHEART, Inc., a privately held developer of percutaneous left atrial appendage management solutions.
- American City Business Journals
AtriCure could pay up to $300M to acquire California firm
AtriCure Inc. disclosed today that the Mason-based medical device maker could pay up to $300 million to acquire a California firm that also makes devices to treat heart ailments.
- Business Wire
AtriCure Enters Into Definitive Agreement to Acquire SentreHEART
AtriCure, Inc. (ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has entered into a definitive agreement to acquire SentreHEART, Inc., a privately held developer of percutaneous left atrial appendage management solutions. Under the terms of the agreement to acquire SentreHEART, the transaction consideration consists of an upfront payment of approximately $40 million in cash and AtriCure common stock, plus additional contingent consideration based on the achievement of certain clinical and reimbursement milestones over the next several years, all of which are value-creating events. Of the contingent consideration, $140 million is based on milestones related to the aMAZE™ IDE clinical trial, including PMA approval, and $120 million is based on a milestone related to reimbursement for the therapy involving SentreHEART devices.
- Thomson Reuters StreetEvents
Edited Transcript of ATRC earnings conference call or presentation 30-Jul-19 8:30pm GMT
Q2 2019 AtriCure Inc Earnings Call
Motley FoolAtriCure Inc (ATRC) Q2 2019 Earnings Call Transcript
ATRC earnings call for the period ending June 30, 2019.
- Zacks
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of 5.56% and 2.31%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
AtriCure Reports Second Quarter 2019 Financial Results
MASON, Ohio-- -- Worldwide revenue of $58.9 million – an increase of 13.7% year over year U.S. revenue of $47.2 million – an increase of 15.5% year over year International revenue of $11.7 million – an increase of 7.0% year over year AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced second quarter 2019 financial results. ...
- ACCESSWIRE
AtriCure, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July, 30 2019 / AtriCure, Inc. (NASDAQ: ATRC ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July, 30 2019 at 4:30:00 PM Eastern ...
- Simply Wall St.
AtriCure (NASDAQ:ATRC) May Be Weighed Down By Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- Zacks
Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
AtriCure to Participate at the Canaccord Genuity 39th Annual Growth Conference
AtriCure, Inc. , a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, today announced that the company will be participating in the upcoming Canaccord Genuity 39th Annual Growth Conference in Boston.
- GuruFocus.com
Atricure Inc (ATRC) President, CEO, & Director Michael H Carrel Sold $800,000 of Shares
President, CEO, & Director of Atricure Inc (ATRC) Michael H Carrel (insider trades) sold 25,000 shares of ATRC on 07/10/2019 at an average price of $32 a share. Continue reading...
- Business Wire
AtriCure to Announce Second Quarter 2019 Financial Results
AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced that it will release its second quarter 2019 financial results on Tuesday, July 30, 2019.
- American City Business Journals
Dayton's largest public company executive compensations
June's final Dayton Business Journal list took a look at the region's public company executive compensations. Of the 24 executives on our list, 66 percent received at least $1 million in total compensation in 2018.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On AtriCure Inc. (ATRC)
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
- Simply Wall St.
Is AtriCure, Inc. (NASDAQ:ATRC) Worth US$29.31 Based On Its Intrinsic Value?
How far off is AtriCure, Inc. (NASDAQ:ATRC) from its intrinsic value? Using the most recent financial data, we'll take...
- CNBC
These stocks have 'underappreciated' stories, Wall Street analysts say
Analysts named Corning, Target, Costco, AtriCure, and Coupa Software as having "underappreciated" stock stories. "Increased control over product supply is an underappreciated part of the Costco investment story," Baird analyst Peter Benedict said.
- Insider Monkey
Hedge Funds Have Never Been More Bullish On AtriCure Inc. (ATRC)
The government requires hedge funds and wealthy investors that crossed the $100 million equity holdings threshold are required to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings disclosed the […]
- Thomson Reuters StreetEvents
Edited Transcript of ATRC earnings conference call or presentation 25-Apr-19 8:30pm GMT
Q1 2019 AtriCure Inc Earnings Call
Motley FoolAtriCure Inc (ATRC) Q1 2019 Earnings Call Transcript
ATRC earnings call for the period ending March 31, 2019.
- Associated Press
AtriCure: 1Q Earnings Snapshot
The Mason, Ohio-based company said it had a loss of 15 cents per share. Losses, adjusted for non-recurring gains, came to 20 cents per share. The results beat Wall Street expectations. The average estimate ...
- Business Wire
AtriCure Reports First Quarter 2019 Financial Results
MASON, Ohio-- -- Worldwide revenue of $54.0 million – an increase of 14.8% year over year U.S. revenue of $43.0 million – an increase of 11.9% year over year International revenue of $11.0 million – an increase of 28.1% year over year AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced first quarter 2019 financial results. ...
- Business Wire
AtriCure Announces First Patient Enrollment in the DEEP IDE Trial Restart
AtriCure, Inc. (ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced the restart of the Dual Epicardial and Endocardial Procedure (DEEP) clinical trial (NCT02393885). Following approval by the FDA to restart the trial and enroll an additional 40 subjects, which was granted in December 2018, the first patient was treated by a team led by Professor Mark La Meir and Professor Carlo de Asmundis at Universitair Ziekenhuis Brussels, Belgium. The DEEP trial is a prospective, multicenter, single arm, investigational device exempt (IDE) study to evaluate the safety and efficacy of the DEEP procedure in treating persistent and long-standing persistent atrial fibrillation.
